Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Genome sequencing of Mycobacterium abscessus isolates from patients in the united states and comparisons to globally diverse clinical strains.

Davidson RM, Hasan NA, Reynolds PR, Totten S, Garcia B, Levin A, Ramamoorthy P, Heifets L, Daley CL, Strong M.

J Clin Microbiol. 2014 Oct;52(10):3573-82. doi: 10.1128/JCM.01144-14. Epub 2014 Jul 23.

2.

In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.

van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL.

Antimicrob Agents Chemother. 2012 Dec;56(12):6324-7. doi: 10.1128/AAC.01505-12. Epub 2012 Oct 1.

3.

The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.

van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL.

Am J Respir Crit Care Med. 2012 Sep 15;186(6):559-65. doi: 10.1164/rccm.201204-0682OC. Epub 2012 Jun 28.

PMID:
22744719
4.

Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease.

van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL.

Int J Antimicrob Agents. 2012 Feb;39(2):173-6. doi: 10.1016/j.ijantimicag.2011.09.019. Epub 2011 Nov 17.

PMID:
22099521
5.

Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?

van Ingen J, Boeree MJ, van Soolingen D, Iseman MD, Heifets LB, Daley CL.

Infect Genet Evol. 2012 Jun;12(4):832-7. doi: 10.1016/j.meegid.2011.10.006. Epub 2011 Oct 20. Review.

PMID:
22036704
6.

XDR tuberculosis.

van Ingen J, de Lange WC, Boeree MJ, Iseman MD, Daley CL, Heifets LB, Böttger EC, van Soolingen D.

Lancet Infect Dis. 2011 Aug;11(8):585. doi: 10.1016/S1473-3099(11)70200-6. No abstract available.

PMID:
21798459
7.

Mycobacterium tuberculosis complex differentiation by genomic deletion patterns with multiplex polymerase chain reaction and melting analysis.

Pounder JI, Anderson CM, Voelkerding KV, Salfinger M, Dormandy J, Somoskovi A, Heifets L, Graham JJ, Storts DR, Petti CA.

Diagn Microbiol Infect Dis. 2010 May;67(1):101-5. doi: 10.1016/j.diagmicrobio.2009.12.014. Epub 2010 Mar 12.

PMID:
20227227
8.

Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs.

Chung WJ, Kornilov A, Brodsky BH, Higgins M, Sanchez T, Heifets LB, Cynamon MH, Welch J.

Tuberculosis (Edinb). 2008 Sep;88(5):410-9. doi: 10.1016/j.tube.2008.06.001.

PMID:
18674969
9.

Nontuberculous mycobacteria in aerosol droplets and bulk water samples from therapy pools and hot tubs.

Glazer CS, Martyny JW, Lee B, Sanchez TL, Sells TM, Newman LS, Murphy J, Heifets L, Rose CS.

J Occup Environ Hyg. 2007 Nov;4(11):831-40.

PMID:
17846927
10.

Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis.

Kisich KO, Gelperina S, Higgins MP, Wilson S, Shipulo E, Oganesyan E, Heifets L.

Int J Pharm. 2007 Dec 10;345(1-2):154-62. Epub 2007 Jun 2.

PMID:
17624699
11.

Pulmonary infection with Mycobacterium neoaurum identified by 16S ribosomal DNA sequence.

Morimoto Y, Chan ED, Heifets L, Routes JM.

J Infect. 2007 Apr;54(4):e227-31. Epub 2007 Feb 15. Review.

PMID:
17306883
12.

Rapid detection of tuberculosis and drug-resistant tuberculosis.

Iseman MD, Heifets LB.

N Engl J Med. 2006 Oct 12;355(15):1606-8. No abstract available.

13.
14.

The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.

Gelperina S, Kisich K, Iseman MD, Heifets L.

Am J Respir Crit Care Med. 2005 Dec 15;172(12):1487-90. Epub 2005 Sep 8. Review.

15.

Ancestral antibiotic resistance in Mycobacterium tuberculosis.

Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, Schnappinger D, Ehrt S, Liu Y, Heifets L, Pieters J, Schoolnik G, Thompson CJ.

Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12200-5. Epub 2005 Aug 15.

16.

Mycobacterial infections caused by nontuberculous mycobacteria.

Heifets L.

Semin Respir Crit Care Med. 2004 Jun;25(3):283-95.

PMID:
16088470
17.

Tuberculosis and other mycobacterial infections.

Heifets L.

Semin Respir Crit Care Med. 2004 Jun;25(3):241-3. No abstract available.

PMID:
16088466
18.

Capreomycin is active against non-replicating M. tuberculosis.

Heifets L, Simon J, Pham V.

Ann Clin Microbiol Antimicrob. 2005 Apr 1;4:6.

19.

Identification of a Mycobacterium tuberculosis strain with stable, low-level resistance to isoniazid.

Madison BM, Siddiqi SH, Heifets L, Gross W, Higgins M, Warren N, Thompson A, Morlock G, Ridderhof JC.

J Clin Microbiol. 2004 Mar;42(3):1294-5.

20.

Cough-generated aerosols of Mycobacterium tuberculosis: a new method to study infectiousness.

Fennelly KP, Martyny JW, Fulton KE, Orme IM, Cave DM, Heifets LB.

Am J Respir Crit Care Med. 2004 Mar 1;169(5):604-9. Epub 2003 Dec 4.

PMID:
14656754
21.

Diagnostic tests: what is rapid and what is inexpensive?

Heifets L.

Int J Tuberc Lung Dis. 2003 Sep;7(9):907; author reply 907-8. No abstract available.

PMID:
12971678
22.

A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs.

Gosling RD, Heifets L, Gillespie SH.

J Antimicrob Chemother. 2003 Sep;52(3):473-6. Epub 2003 Jul 29.

PMID:
12888596
23.

WHO and Russia: the turning point in joint efforts against TB.

Heifets L.

Int J Tuberc Lung Dis. 2003 Feb;7(2):101-2. No abstract available.

PMID:
12588008
24.

Leo Tolstoy, TB in Russia, and American perceptions.

Heifets L, Iseman MD.

Int J Tuberc Lung Dis. 2002 Nov;6(11):939-41. No abstract available.

PMID:
12475138
25.

Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.

Larsen MH, Vilchèze C, Kremer L, Besra GS, Parsons L, Salfinger M, Heifets L, Hazbon MH, Alland D, Sacchettini JC, Jacobs WR Jr.

Mol Microbiol. 2002 Oct;46(2):453-66.

26.

Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils.

Kisich KO, Higgins M, Diamond G, Heifets L.

Infect Immun. 2002 Aug;70(8):4591-9.

27.

In search of rapid diagnosis and drug-resistance detection tools: is the FASTPlaqueTB test the answer?

Takiff H, Heifets L.

Int J Tuberc Lung Dis. 2002 Jul;6(7):560-1. No abstract available.

PMID:
12102292
28.

Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

Heifets L.

J Med Microbiol. 2002 Jan;51(1):11-2. No abstract available.

PMID:
11800467
29.

False diagnosis of tuberculosis.

Heifets L.

Int J Tuberc Lung Dis. 2001 Sep;5(9):789-90. No abstract available.

PMID:
11573889
31.

Are we on the brink of a new white plague in Russia?

Heifets L, Iseman MD.

Int J Tuberc Lung Dis. 2000 Dec;4(12):1095-6. No abstract available.

PMID:
11144449
32.

Three stories about green eggs

Heifets L.

Int J Tuberc Lung Dis. 2000 Nov;4(11):1088. No abstract available.

PMID:
11092725
33.

Three stories about green eggs. Story one: Green Eggs and freedom.

Heifets L.

Int J Tuberc Lung Dis. 2000 Oct;4(10):988-9. No abstract available.

PMID:
11055768
34.

Immunologic diagnosis of tuberculosis: a review.

Chan ED, Heifets L, Iseman MD.

Tuber Lung Dis. 2000;80(3):131-40. Review.

PMID:
10970761
35.

Dilemmas and realities of rapid diagnostic tests for tuberculosis.

Heifets L.

Chest. 2000 Jul;118(1):4-5. No abstract available.

PMID:
10893347
36.
37.

Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team.

Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, Powderly WG, Notario GF, Wynne BA, Hafner R.

J Infect Dis. 2000 Apr;181(4):1289-97. Epub 2000 Apr 13.

PMID:
10762562
38.
39.

Mycobacterium terrae: case reports, literature review, and in vitro antibiotic susceptibility testing.

Smith DS, Lindholm-Levy P, Huitt GA, Heifets LB, Cook JL.

Clin Infect Dis. 2000 Mar;30(3):444-53. Review.

PMID:
10722426
40.
41.

pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.

Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y.

Antimicrob Agents Chemother. 2000 Mar;44(3):528-32.

42.

A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS.

Cohn DL, Fisher EJ, Peng GT, Hodges JS, Chesnut J, Child CC, Franchino B, Gibert CL, El-Sadr W, Hafner R, Korvick J, Ropka M, Heifets L, Clotfelter J, Munroe D, Horsburgh CR Jr.

Clin Infect Dis. 1999 Jul;29(1):125-33.

PMID:
10433575
43.

Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century.

Heifets LB, Cangelosi GA.

Int J Tuberc Lung Dis. 1999 Jul;3(7):564-81. Review.

PMID:
10423219
44.

Dilemmas and realities in the laboratory diagnosis of tuberculosis in low income countries.

Heifets L, Lindholm-Levy P.

Int J Tuberc Lung Dis. 1999 Feb;3(2):88-9. No abstract available.

PMID:
10091872
45.

Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.

Heifets L, Sanchez T, Vanderkolk J, Pham V.

Antimicrob Agents Chemother. 1999 Jan;43(1):25-8.

47.
48.

Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.

Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP.

Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.

49.

Susceptibilities of Mycobacterium malmoense determined at the growth optimum pH (pH 6.0).

Heginbothom ML, Lindholm-Levy PJ, Heifets LB.

Int J Tuberc Lung Dis. 1998 May;2(5):430-4.

PMID:
9613641
50.

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG).

el-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, Olibrice M, Medard F, Chirgwin KD, Mildvan D, Jones BE, Telzak EE, Klein O, Heifets L, Hafner R.

Clin Infect Dis. 1998 May;26(5):1148-58.

PMID:
9597244

Supplemental Content

Loading ...
Support Center